The purpose of this clinical study was to investigate the influence of concomitant drug therapy with ciprofloxacin and rifampin on the individual pharmacokinetic profile of each agent in elderly patients. Twelve nursing home patients (age, 74 7 years), colonized with methiiillin-resistant Staphylococcus aureus, were randomized to receive 14-day therapy with oral ciprofloxacin (750 mg every 12 h) (group A; n = 6) or ciprofloxacin (750 mg every 12 h) and oral rifampin (300 mg every 12 h) (group B; n = 6). Serial blood samples were obtained from 0 to 12 h following ciprofloxacin doses 1 and 13 and from 0 to 36 h after the last ciprofloxacin dose. No significant differences (P > 0.05) were found between or within groups in any pharmacokinetic parameter. The mean ciprofloxacin oral clearance values were 0.35 ± 0.06, 0.41 ± 0.15, and 0.38 ± 0.11 liter/h per kg for doses 1, 13, and 28, respectively, in group A patients. The mean oral clearance values in group B patients for the respective doses were 0.53 ± 0.36, 0.32 ± 0.13, and 0.36 ± 0.17 liter/h per kg. Likewise, no significant differences (P > 0.05) in rifampin pharmacokinetic parameters were found when compared with historical controls. These data suggest that ciprofloxacin and rifampin may be given concomitantly in standard clinical dosing regimens. The combination results in therapeutic levels of both drugs and appears to be safe for adminiration to elderly nursing home patients.
Colonization and infection with methicillin-resistant Staphylococcus aureus are becoming serious problems among debilitated patients and those in chronic care institutions, such as nursing homes (10) . Combination therapy with ciprofloxacin and rifampin is a potential regimen for treatment of these conditions. The addition of rifampin to various antistaphylococcal regimens has been shown to enhance their bactericidal activity in animal models (4, 11, 16) . The combination of these antimicrobial agents may prove to be useful and provide better therapeutic outcomes.
Ciprofloxacin and other metabolized quinolones undergo biotransformation via the hepatic microsomal cytochrome P-450 system. Concomitant use of ciprofloxacin and other drugs that share the same site of metabolism has resulted in elevated concentrations of those other drugs in plasma (20, 23, 25, 26) . Rifampin, a classic enzyme inducer, is also metabolized by the microsomal enzyme system (1, 3). Consequently, concurrent therapy with the antibiotics ciprofloxacin and rifampin may affect the disposition of one another. The purpose of this clinical research was to explore the influence of concomitant drug therapy with ciprofloxacin and rifampin on their individual pharmacokinetic profiles.
MATERIALS AND METHODS Subjects. Twelve elderly male nursing home residents were enrolled after informed consent was obtained. The ages of the study subjects ranged from 67 to 95 years (mean, 74). All patients were documented to have methicillin-resistant S. aureus colonization of the nares. The patients had no surgical or medical condition known to alter the disposition of ciprofloxacin or rifampin. Exclusion criteria included the following: history of allergy to quinolones; inability to take medications by mouth; serum creatinine level of >3 mg/dl; * Corresponding author. concurrent therapy with theophylline or warfarin; abnormal liver function tests; and anemia (defined as a hemoglobin level of <11 g/dl or hematocrit below 34%) (17) . The subjects did not consume any caffeine-containing foods or beverages or alcoholic beverages, beginning at least 48 h before and throughout the study period. None of the subjects smoked cigarettes.
Protocol. The study protocol and consent form were approved by our institutional review board. Subjects were randomized to one of two treatment groups. Group A patients received one 750-mg ciprofloxacin tablet (Miles Inc. Pharmaceutical Division, West Haven, Conn.) orally every 12 h for 14 days. Group B patients received, in addition to ciprofloxacin orally every 12 h for 14 days, one 300-mg rifampin capsule (CIBA Pharmaceuticals, Summit, N.J.) orally every 12 h for 14 days. The first rifampin dose began with the second ciprofloxacin dose (Fig. 1) . On blood sampling days, the doses were ingested with 180 ml of tap water after an 8-h fast, and food was withheld for an additional 4 h. Patients on continuous tube feedings (n = 3 in each group) fasted for 2 h prior to and 4 h after each dose. In patients for whom antacid and histamine H2-blocker therapy could not be discontinued, these medications were omitted on the pharmacokinetic study day until at least 4 h after dosing with ciprofloxacin. One subject in group A had been on previous rifampin therapy; five subjects in group B had been on previous rifampin therapy. No subject, however, had received rifampin within 2 months prior to the study period.
Blood samples for pharmacokinetic analysis were obtained through an indwelling heparin lock placed in a forearm vein. The blood samples (10 the last ciprofloxacin dose. The samples were allowed to clot at room temperature, and the serum was separated by centrifugation. Each group B sample was divided into two polyethylene storage vials to allow separate assays of ciprofloxacin and rifampin. All serum samples were stored at -70°C until analysis.
Analysis. Serum ciprofloxacin samples were analyzed by using a high-performance liquid chromatography procedure with fluorescence detection (18) . Standard curves were linear from 0.1 to 8.0 p.g/ml (r = 0.999). The lowest concentration of standard used routinely was 0.1 ,ug/ml. The intraday coefficients of variation at ciprofloxacin concentrations of 0.1, 1.0, and 8.0 ,ug/ml were 9.7, 2.1, and 5.4% (n = 4), respectively. The interday coefficients of variation, at the same concentrations, were 12.4, 8.7, and 0.6% (n = 4), respectively. Rifampin concentrations were quantitated by high-performance liquid chromatography with UV detection (14) . Standard curves were linear from 0 to 20 ,ug/ml (r = 0.998). The minimum detectable level was 0.2 ,ug/ml. The lowest concentration of standard used routinely was 5 ,ug/ml. The intraday coefficients of variation at rifampin concentrations of 5, 10, 15, and 20 jig/ml were 5.0, 2.5, 1.1, and 1.7% (n = 2), respectively. The interday coefficients of variation, at the same concentrations, were 6.9, 2.2, 3.6, and 2.4% (n = 4), respectively. Pharmacokinetic parameters. Pharmacokinetic parameters for ciprofloxacin and rifampin were calculated by noncompartmental methods. The maximum concentration of drug in serum (Cmax) and the time to the maximum concentration of drug in serum (Tm.) were determined directly by observation of the data. The area under the concentration-time curve (AUC) from 0 h to Xo for the first ciprofloxacin dose was determined by the trapezoidal rule. The values were extrapolated to infinity by dividing the last measured concentration in serum by P, the slope of the terminal elimination phase obtained by least-squares linear regression. The AUC from 0 to 12 h was calculated via the trapezoidal rule for doses 13 and 28 of ciprofloxacin and doses 12 and 27 of rifampin. The elimination half-life (t4/2) was calculated by ln 2 divided by ,B.
The presumed tissue washout terminal elimination half-life, a parameter proposed by Guay et al. (9) , for ciprofloxacin was calculated from serum concentration-versus-time data from 12 to 36 h postdose. The apparent oral clearance (CLO) was determined by dividing the dose by the AUC and standardizing to body weight. Creatinine clearance (CLCR) was estimated by the method of Cockcroft and Gault (6) and standardized to 1.73 m2 body surface area.
Statistics. Statistical comparison of group A and group B demographic data was performed by using the MannWhitney test (age, body weight, CLCR). Two-way analysis of variance with repeated measures (followed by Fisher's least significant difference test, if appropriate) was used to assess (27) .
RESULTS
The ages, weights, and estimated CLCRs of the subjects are presented in Table 1 [SD] ) ciprofloxacin serum concentration-time profiles from both subject groups are depicted in Fig. 2 . The mean (±SD) rifampin serum concentration-time profile for group B subjects is shown in Fig. 3 . significantly different (P > 0.05) between groups A and B (6.5 ± 2.6 versus 4.6 ± 1.3 h, respectively).
Rifampin pharmacokinetic parameters (Cmax, Tmax, 13, AUC, and CLO) and their corresponding historical control values (2), when pertinent, are summarized in Table 4 . No significant differences (P > 0.05) existed between pharmacokinetic parameters determined from dose 12 versus dose 27 data. Likewise, our pharmacokinetic parameters did not differ significantly (P > 0.05) from those of historical controls (2). The mean t412 values were 2.66 ± 1.57 (dose 12), 2.32 ± 0.99 (dose 27), and 4.09 ± 6.34 (historical control) h (P > 0.05). 
DISCUSSION
Currently, approximately 1.5 million Americans reside in skilled-nursing facilities (22) . On a given day, more patients reside in nursing homes than in acute care settings (5). Methicillin-resistant S. aureus colonization and infection are increasing problems among chronic care patients in nursing homes (10) . Combination oral therapy with ciprofloxacin plus rifampin provides an attractive potential treatment for these conditions and other infections not only in nursing homes but in the outpatient setting as well (4, 11, 16) .
In humans, rifampin is a potent inducer of drug metabolism (1, 3). Rifampin has been shown to produce proliferation of hepatic smooth endoplasmic reticulum and increases in cytochrome P-450 content (3, 12) . Ciprofloxacin undergoes hepatic oxidative metabolism, with approximately 15% of a dose converted to three main metabolites (sulfociprofloxacin, oxociprofloxacin, and desethylene-ciprofloxacin) (32) . Recently, Barriere et al. demonstrated a significant increase in ciprofloxacin clearance in rabbits after 6 days of rifampin therapy (4).
Previous reports also suggest an increase in theophylline and caffeine levels in the presence of ciprofloxacin (20, 23, 25, 26) . It is plausible that these interactions are the result of inhibition of drug metabolism by ciprofloxacin at the hepatic microsomal P-450 level, at which these agents are metabolized (23) . Consequently, the possibility of enhanced ciprofloxacin clearance and/or reduced rifampin clearance led to our pharmacokinetic evaluation of concurrent ciprofloxacin and rifampin therapy in elderly nursing home patients.
Pharmacokinetic parameters under evaluation consisted of Cmax Tmax, P, t1/2, AUC, and CLo. We evaluated CLo since this parameter reflects absorption, first-pass extraction, and elimination (8) . On the other hand, we chose not to calculate the volume of distribution since this parameter is dependent upon bioavailability and would not offer meaningful comparisons with oral dosing, in this case.
Our findings demonstrate no significant difference in ciprofloxacin pharmacokinetic parameters either between or within (dose 1 versus 13 versus 28) the ciprofloxacin treatment group and the ciprofloxacin and rifampin treatment group. Likewise, no significant differences in rifampin pharmacokinetic parameters occurred, compared with historical controls (2) .
A number of explanations for these findings are possible. First, selectivity exists in the enzyme induction effect of rifampin, and thus an induction phenomenon would not be expected for every drug undergoing hepatic oxidative metabolism (15) . Second, wide interspecies differences in drug metabolism exist, and the presence of an enzyme induction effect in animals is not usually predictive of occurrences in humans (4). Third, several clinical studies have suggested a decrease in enzyme induction effects in the elderly by rifampin and other inducers (24, 28, 29, 33) . Finally, the most likely explanation for the absence of a significant effect of rifampin on ciprofloxacin clearance in our elderly patients is related to the extent of hepatic metabolism of ciprofloxacin. Ciprofloxacin is excreted primarily by the kidneys (7, 30) . Since the group A and group B subjects were well matched for renal function, any observed differences in CLo for ciprofloxacin could be attributed to changes in metabolism. Hepatic oxidative metabolism accounts for only 15% of the clearance of ciprofloxacin, and our study was designed to detect a 50% change in clearance. However, rifampin is metabolized in the liver mainly by desacetylation and hydrolysis and its urinary clearance is only 12% of the glomerular filtration rate (13) . Consequently, the maximum possible effect of ciprofloxacin on rifampin clearance was greater than 50%, but we did not find a significant change.
The wide intra-and interpatient variabilities in pharmacokinetic disposition of ciprofloxacin and rifampin in our elderly subjects may stem from the heterogeneity of their disease states and concurrent medications. This heterogeneity is not surprising; the intensity of medication use by nursing home patients is well documented in the literature (5) . Both phenytoin and carbamazepine have enzyme-inducing properties (19) , whereas diltiazem has been reported to inhibit the metabolism of various xenobiotics (21) . Subjects 6, 8, and 11 were taking one to all three of these medications while participating in our study. However, the concomitant administration of these medications with ciprofloxacin or ciprofloxacin and rifampin did not appear to increase the intra-or interpatient variability in ciprofloxacin or rifampin pharmacokinetic parameters. No patterns in intra-and interindividual variabilities were observed.
All of our patients were in a stable state of health throughout the study period. Furthermore, attempts were made to In summary, our data do not indicate the occurrence of a major pharmacokinetic interaction between ciprofloxacin and rifampin in elderly patients. The data demonstrate wide intra-and interpatient variabilities. However, our findings suggest that the usual clinical dosing regimens for ciprofloxacin and rifampin may be used when administering both drugs concomitantly. Therapeutic levels of both drugs are achieved, and the combination appears to be safe for concomitant administration to elderly nursing home patients. However, future studies are warranted to fully evaluate the potential for an interaction between ciprofloxacin and rifampin in younger patients.
